Segulah Medical Acceleration Announces Investment in Signifier Medical Technologies
Segulah Medical Acceleration AB (SMA) announced today that it has invested in UK-based Signifier Medical Technologies’ USD 35 million Series D convertible financing. The financing was jointly led by SMA together with Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.
Signifier is commercializing proprietary technologies to address the root causes of sleep disordered breathing and are focused on the development of innovative and non-invasive solutions for patients with conditions such as obstructive sleep apnoea (OSA) and primary snoring. This series D financing will underpin the commercialization of Signifier’s FDA-approved De Novo device and therapy, eXciteOSA, to treat millions of patients around the world suffering from primary snoring and mild OSA.
OSA affects an estimated one billion adults aged 30 to 69 globally, with 60% having mild OSA. The disease is linked to a number of comorbidities, such as hypertension, stroke, heart failure, diabetes, depression, and an increased risk of road traffic accidents. In contrast to complex night-time wearables commonly used to treat OSA, eXciteOSA provides a low-burden, patient-friendly option of daytime therapy. Patients are guided by an intuitive Smartphone App, monitored remotely by their physician, and supported by Signifier’s world-class Patient Advocate support team. Extensive clinical trials and real-world usage indicate high (>80%) adherence to therapy, as confirmed by over 25,000 successfully completed daily therapies which have been recorded through Signifier’s App.
“Segulah Medical is delighted to be co-leading Signifier Medical’s Series D convertible financing. Our focus on providing growth capital to young companies based in Europe fits well with Signifier Medical’s requirement to fund the execution of its commercial strategy and continued investment in clinical trials and new product development. We are very excited about the prospects for eXciteOSA as a revolutionary daytime therapy to treat OSA. With an estimated 25% of the global adult population suffering from sleep disordered breathing, we believe that eXciteOSA will become the first line therapy for these patients.” said Roger Gunnarsson, Managing Partner at SMA.
“Our Series D fund raise will enable Signifier to bring our novel therapy to millions of patients suffering from sleep disordered breathing for whom there is today no effective treatment. We are truly grateful for the strong support the Company has received from both our existing shareholders and new investors which provides strong validation of our technology, team and commercial strategy.” said Akhil Tripathi, the CEO of Signifier
-Ends-
For more information about Segulah Medical Acceleration, please contact:
SMA
Roger Gunnarsson (gunnarsson@segulahmedical.com)
+46 73 850 67 32
About Signifier Medical Technologies
Signifier Medical Technologies is a pioneer in understanding and addressing the root causes of sleep disordered breathing. They are focused on the development and commercialization of innovative and non-invasive solutions for patients with conditions such as OSA and primary snoring. Founded in 2015, Signifier Medical Technologies is at the forefront of sleep therapy, focused on developing therapies that put patient experience and comfort first. UK based Signifier has offices in London (UK), Needham (Massachusetts, USA) and Berlin (Germany). https://signifiermedical.com/
About Segulah Medical Acceleration AB
Segulah Medical Acceleration (SMA) is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe. SMA’s objective is to help its partner companies accelerate growth and reach commercial proof of concept. SMA’s geographic remit is Scandinavia and other Western European countries. The areas within Medtech that SMA prioritizes include medical devices and consumables, diagnostics, life science tools, and digital technologies (AI). SMA has more than SEK 1.25 billion (€ 125m equivalent) in investable funds. https://segulahmedical.com/
CytaCoat and Absorbest announce development and licensing agreement for superabsorbent advanced wound care dressings
2024.09.06CytaCoat AB and Absorbest AB have entered into a development and licensing agreement to bring CytaCoat’s unique performance enhancing coating technologies to market in superabsorbent advanced wound dressings.
Read moreSegulah Medical Acceleration announces investment in Senzime
2023.09.28Segulah Medical Acceleraion AB (“SMA”) has made a commitment regarding an investment in Senzime AB (publ) (“Senzime” or “the Company”). As previously communicated in a press release from the Company, Senzime’s board of directors has resolved on a directed share issue of SEK 117 million, led by SMA together with Carnegie Fonder and existing shareholders Fjärde AP-fonden, Crafoordska Stiftelsen, Handelsbanken Fonder, Fredrik Rapp, and Swedbank Robur.
Read moreCollective Minds Radiology announces closing of SEK 84m financing, led by Segulah Medical Acceleration and existing shareholders
2023.08.28Collective Minds Radiology, a fast-growing, Swedish health-tech company with a mission to build the world’s largest platform and community for healthcare collaboration, announces the closing of a SEK 84 million funding round. The round was led by Segulah Medical Acceleration (“SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, Brightly Ventures, Tradecity, Crista Galli Ventures, and several European business angels. The funding will enable Collective Minds to accelerate the commercial expansion of its professional healthcare collaboration platform for clinical consultation, education, and clinical research, with the aim of increasing the quality of care.
Read moreNavinci appoints Eva Pisa as chairman, further strengthens the leadership team and establishes a Scientific Advisory Board
2023.02.20In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr. Caroline Gallant as new CTO and the formation of a Scientific Advisory Board chaired by Professor Ulf Landegren.
Read moreAllurion to Go Public on NYSE
2023.02.16SMA portfolio company Allurion Technologies, a global leader in weight loss technology, to become publicly listed through business combination
Read moreSegulah Medical Acceleration Announces Investment in Allurion Technologies
2022.09.13Segulah Medical Acceleration AB (“SMA”) has made a minority investment in US-based Allurion Technologies during their July 2021 extension of the $34m Series D financing. The Series D round was led by Novalis LifeSciences and Romulus Capital.
Read moreSegulah Medical Acceleration Announces Investment in Navinci Diagnostics
2022.07.12Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.
Read moreSignifier Medical Technologies is granted HCPCS Codes
2022.02.28Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology
Read moreSegulah Medical Acceleration Announces Investment in Signifier Medical Technologies
2021.07.30Segulah Medical Acceleration AB (SMA) announced today that it has invested in UK-based Signifier Medical Technologies’ USD 35 million Series D convertible financing. The financing was jointly led by SMA together with Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.
Read moreSegulah Medical Acceleration Announces Investment in SAGA Diagnostics
2021.06.30Segulah Medical Acceleration AB (SMA) announced today that it has invested in cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million (€10.5 million) Series A2 equity financing round. The round was led by SMA together with the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.
Read moreSegulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies
2021.06.28Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.
Read moreBlue chip investors back new MedTech investment company
2021.04.29Segulah Medical Acceleration, SMA, is a newly formed company specializing in medical technology investments, with a focus on Sweden, Scandinavia and Western Europe. The company is financed by leading institutions and prominent private investors, whose initial commitments amount to approximately SEK 1.2 billion.
Read more